Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
Journal of Drugs in Dermatology · 2024-08-01 · 23 (8) · 632-639
DOI: 10.36849/jdd.7486 ↗At a glance
Journal article in Journal of Drugs in Dermatology, published online on 2024-07-01. Written by Luigi Gargiulo and 9 co-authors. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Cited 7 times so far (Crossref).
Abstract (original language)
BACKGROUND: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited. MATERIALS AND METHODS: We conducted a 104-week monocentric retrospective study on 102 psoriasis patients, all treated with guselkumab for at least 16 weeks. At each visit, we used the Psoriasis Area and Severity Index (PASI): effectiveness endpoints were the percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI compared with baseline. The Kaplan-Meier curve was used to assess the drug survival. RESULTS: At week 16, PASI 90 and PASI 100 were achieved by 49.02% and 32.35% of patients. At week 52, PASI 90 and PASI 100 were achieved by 71.58% and 55.79% of patients. After 2 years, PASI 90 and PASI 100 were achieved by 79.63% and 61.11% of patients. Obese and overweight patients had comparable PASI 90 and PASI 100 responses throughout the study. At week 104, no significant differences were observed between bio-naïve and bio-experienced patients regarding all effectiveness endpoints. No significant safety signals were reported in our study. After 24 months, 91.57% of our cohort was still on treatment with guselkumab. CONCLUSION: Our findings, although limited by the study's retrospective nature, confirm that guselkumab is a safe and effective therapeutic option for a "real-life" cohort of patients with psoriasis. J Drugs Dermatol. 2024;23(8):632-639. doi:10.36849/JDD.7486R1.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Gargiulo, L., Ibba, L., Cortese, A., Toso, F., Vignoli, C. A., Fiorillo, G., Piscazzi, F., Valenti, M., Costanzo, A., & Narcisi, A. (2024). Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology, 23(8), 632-639. https://doi.org/10.36849/jdd.7486
Vancouver
Gargiulo L, Ibba L, Cortese A, Toso F, Vignoli CA, Fiorillo G, et al. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology. 2024;23(8):632-639. doi:10.36849/jdd.7486
BibTeX
@article{Gargiulo2024,
author = {Gargiulo, Luigi and Ibba, Luciano and Cortese, Andrea and Toso, Francesco and Vignoli, Carlo A and Fiorillo, Giovanni and Piscazzi, Francesco and Valenti, Mario and Costanzo, Antonio and Narcisi, Alessandra},
title = {Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study},
journal = {Journal of Drugs in Dermatology},
year = {2024},
volume = {23},
number = {8},
pages = {632--639},
doi = {10.36849/jdd.7486}
}
EUVIMED